Isoprinosine does not protect against frequent respiratory
tract infections in childhood

J 1999

Isoprinosine does not protect against frequent respiratory tract infections in childhood

LITZMAN, Jiří, Jindřich LOKAJ, Marcela KREJČÍ, Sáva PEŠÁK, Gareth MORGAN et. al.

Základní údaje

Originální název

Isoprinosine does not protect against frequent respiratory tract infections in childhood

Autoři

LITZMAN, Jiří (203 Česká republika, garant), Jindřich LOKAJ (203 Česká republika), Marcela KREJČÍ, Sáva PEŠÁK (203 Česká republika) a Gareth MORGAN

Vydání

Eur. J. Pediatr, Berlin, Springer-Verlag, 1999, 0340-6199

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30209 Paediatrics

Stát vydavatele

Německo

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 1.280

Kód RIV

RIV/00216224:14110/99:00001564

Organizační jednotka

Lékařská fakulta

UT WoS

000077651800007

Klíčová slova anglicky

Immunotherapy; Inosine pranobex; lymphocyte subsets; respiratory tract infections

Štítky

Immunotherapy, Inosine pranobex, lymphocyte subsets, respiratory tract infections

Změněno: 18. 6. 2009 11:43, prof. MUDr. Jiří Litzman, CSc.

Anotace

ORIG CZ

V originále

Isoprinosine, an in vitro immuno-enhancing agent principally acting by stimulating T-lymphocytes, is one of a number of agents sometimes used in an attempt to prevent recurrent respiratory infections in children, although there are no formal trials for this particular drug. We performed a placebo-controlled double-blind trial to assess the efficacy of isoprinosine (50 mg/kg per day) for 6 weeks followed by 50 mg/kg per day twice weekly for 6 weeks in the prevention of frequent acute respiratory tract infections in 102 children aged 4-8 years. A total of 43 children treated with isoprinosine and 41 with placebo finished the study. Despite a transient increase in the total number of CD3+, CD4+ and CD8+ T-lymphocytes after 6 weeks of daily isoprinosine treatment, there was no difference in the number and length of duration of acute respiratory infections, number of antibiotic courses and number of days with cough, pharyngitis, rhinitis and increased body temperature (> or = 37.0 degrees C and > or = 38.0 degrees C). There were no changes in markers of T- or B-lymphocyte activation (CD25, HLA-DR, CD45RA/RO, CD23). CONCLUSION: Attempts at immunomodulation using isoprinosine in the dose and for the duration used may increase the total numbers of both CD4 and CD8 T-lymphocytes but is ineffective in prevention of respiratory tract infections in childhood.

Česky

Isoprinosin je neúčinný u dětí s častými respiračními infekcemi.

Návaznosti

IZ2169, projekt VaV

Název: Imunomodulace v léčbě dětí s častými infekcemi.

Investor: Ministerstvo zdravotnictví ČR, Imunomodulace v léčbě dětí s častými infekcemi

Citovat

LITZMAN, Jiří, Jindřich LOKAJ, Marcela KREJČÍ, Sáva PEŠÁK a Gareth MORGAN. Isoprinosine does not protect against frequent respiratory tract infections in childhood. Eur. J. Pediatr. Berlin: Springer-Verlag, 1999, roč. 158, č. 1, s. 32-37. ISSN 0340-6199.

@article{226272,
   author = {Litzman, Jiří and Lokaj, Jindřich and Krejčí, Marcela and Pešák, Sáva and Morgan, Gareth},
   article_location = {Berlin},
   article_number = {1},
   keywords = {Immunotherapy; Inosine pranobex; lymphocyte subsets; respiratory tract infections},
   language = {eng},
   issn = {0340-6199},
   journal = {Eur. J. Pediatr},
   title = {Isoprinosine does not protect against frequent respiratory tract infections in childhood},
   volume = {158},
   year = {1999}
}

TY  - JOUR
ID  - 226272
AU  - Litzman, Jiří - Lokaj, Jindřich - Krejčí, Marcela - Pešák, Sáva - Morgan, Gareth
PY  - 1999
TI  - Isoprinosine does not protect against frequent respiratory tract infections in childhood
JF  - Eur. J. Pediatr
VL  - 158
IS  - 1
SP  - 32
EP  - 32
PB  - Springer-Verlag
SN  - 03406199
KW  - Immunotherapy
KW  - Inosine pranobex
KW  - lymphocyte subsets
KW  - respiratory tract infections
N2  - Isoprinosine, an in vitro immuno-enhancing agent principally acting by stimulating T-lymphocytes, is one of a number of agents sometimes used in an attempt to prevent recurrent respiratory infections in children, although there are no formal trials for this particular drug. We performed a placebo-controlled double-blind trial to assess the efficacy of isoprinosine (50 mg/kg per day) for 6 weeks followed by 50 mg/kg per day twice weekly for 6 weeks in the prevention of frequent acute respiratory tract infections in 102 children aged 4-8 years. A total of 43 children treated with isoprinosine and 41 with placebo finished the study. Despite a transient increase in the total number of CD3+, CD4+ and CD8+ T-lymphocytes after 6 weeks of daily isoprinosine treatment, there was no difference in the number and length of duration of acute respiratory infections, number of antibiotic courses and number of days with cough, pharyngitis, rhinitis and increased body temperature (> or = 37.0 degrees C and > or = 38.0 degrees C). There were no changes in markers of T- or B-lymphocyte activation (CD25, HLA-DR, CD45RA/RO, CD23). CONCLUSION: Attempts at immunomodulation using isoprinosine in the dose and for the duration used may increase the total numbers of both CD4 and CD8 T-lymphocytes but is ineffective in prevention of respiratory tract infections in childhood.
ER  -

LITZMAN, Jiří, Jindřich LOKAJ, Marcela KREJČÍ, Sáva PEŠÁK a Gareth MORGAN. Isoprinosine does not protect against frequent respiratory tract infections in childhood. \textit{Eur. J. Pediatr}. Berlin: Springer-Verlag, 1999, roč.~158, č.~1, s.~32-37. ISSN~0340-6199.

Podrobný výpis o publikaci